In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility

A post hoc analysis of two randomized, placebo –controlled, Phase 3 trials of intravenous reslizumab, an anti-interleukin-5 (IL-5) biologic for severe eosinophilic asthma.

Source: Allergy, Asthma and Clinical Immunology - April 19, 2020 Category: Allergy & Immunology Authors: J. Christian Virchow, Lisa Hickey, Evelyn Du and Margaret Garin Tags: Short report Source Type: research